Galapagos Reports the First Patient Dosing of GLPG3667 in the P-II Study (GALARISSO) for the Treatment of Dermatomyositis
Shots:
- The first patient has been dosed in the P-II trial (GALARISSO) evaluating the efficacy, safety, tolerability, PK & PD of GLPG3667 (150mg, qd) vs PBO in ~62 adult patients with DM for 24wks.
- The 1EPs of the study is the proportion of patients with minimal improvement in the signs and symptoms of DM @24wk.
- GLPG3667 is a novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor & is currently in development for the treatment of inflammatory and auto-immune diseases. If GLPG3667 is approved, it has the potential to be the first selective oral TYK2 inhibitor for dermatomyositis
Ref: Globe Newswire | Image: Galapagos
Related News:- Galapagos Reports Results of GLPG3667 in P-Ib Study for the Treatment of Psoriasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
